1jld: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="1jld" size="450" color="white" frame="true" align="right" spinBox="true" caption="1jld, resolution 2.5Å" /> '''POTENT HIV PROTEASE ...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1jld.gif|left|200px]]<br />
[[Image:1jld.gif|left|200px]]<br /><applet load="1jld" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1jld" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1jld, resolution 2.5&Aring;" />
caption="1jld, resolution 2.5&Aring;" />
'''POTENT HIV PROTEASE INHIBITORS CONTAINING A NOVEL (HYDROXYETHYL)AMIDE ISOSTERE'''<br />
'''POTENT HIV PROTEASE INHIBITORS CONTAINING A NOVEL (HYDROXYETHYL)AMIDE ISOSTERE'''<br />


==Overview==
==Overview==
A series of HIV protease inhibitors containing a novel, (hydroxyethyl)amidosuccinoyl core has been synthesized. These, peptidomimetic structures inhibit viral protease activity at low nanomolar, concentrations (IC50 &lt; 10 nM for HIV-1 protease). The inhibition constant, (Ki) for inhibitor 19 was determined to be 7.5 pM against HIV-1 and 1.2 nM, against HIV-2 proteases, respectively. Several compounds (19-24) inhibited, HIV-1 replication in cell culture assays with 50% effective concentrations, (EC50) = 3.7-35 nM. This series of inhibitors was found to exhibit poor, bioavailability (&lt; 10%) in the rat, following oral administration. The, synthesis and biological properties of these compounds are discussed. In, addition, an X-ray structure of one of these inhibitors (23) in complex, with HIV-2 protease provides insight into the binding mode of this novel, class of HIV protease inhibitors.
A series of HIV protease inhibitors containing a novel (hydroxyethyl)amidosuccinoyl core has been synthesized. These peptidomimetic structures inhibit viral protease activity at low nanomolar concentrations (IC50 &lt; 10 nM for HIV-1 protease). The inhibition constant (Ki) for inhibitor 19 was determined to be 7.5 pM against HIV-1 and 1.2 nM against HIV-2 proteases, respectively. Several compounds (19-24) inhibited HIV-1 replication in cell culture assays with 50% effective concentrations (EC50) = 3.7-35 nM. This series of inhibitors was found to exhibit poor bioavailability (&lt; 10%) in the rat, following oral administration. The synthesis and biological properties of these compounds are discussed. In addition, an X-ray structure of one of these inhibitors (23) in complex with HIV-2 protease provides insight into the binding mode of this novel class of HIV protease inhibitors.


==About this Structure==
==About this Structure==
1JLD is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] with QNC as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1JLD OCA].  
1JLD is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] with <scene name='pdbligand=QNC:'>QNC</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1JLD OCA].  


==Reference==
==Reference==
Line 21: Line 20:
[[Category: polyprotein]]
[[Category: polyprotein]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov  8 14:13:09 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:24:02 2008''